In total, Lian has publicly offered to purchase over 120 million shares of IMP (77.94% of its charter capital). The offer price is set at 57,400 VND per share, amounting to an estimated expenditure of approximately 6.9 trillion VND. At this price, IMP is valued at 8.8 trillion VND.
In reality, Livzon’s plan to acquire IMP was announced in late May 2025 through a share purchase agreement. Based on the shareholder structure, Livzon intends to acquire shares from three major shareholders: SK Investment (holding nearly 73.5 million shares, equivalent to 47.69%), Binh Minh Kim Investment JSC (Sunrise) (over 15 million shares, 9.75%), and KBA Investment JSC (nearly 11.4 million shares, 7.37%).
Notably, according to the disclosed agreement, Livzon initially planned to acquire only 64.81% of IMP’s capital, which is 13% lower than the actual offer. The additional shares are likely to come from major shareholder Pharmaceutical Vietnam (UPCoM: DVN), which currently holds 22.04% of IMP’s capital.
List of major shareholders of IMP. Source: VietstockFinance
|
The sale of IMP was hinted at by SK Group during the 2025 Annual General Meeting. Specifically, Sung Min Woo, Chairman of IMP’s Board of Directors and representative of SK Group, stated that although no divestment had occurred, “SK is restructuring its entire portfolio, including all SK assets globally. Therefore, there may be changes in SK’s ownership ratio in Imexpharm in the future” – quoted from the Chairman of IMP.
SK Group Sells Imexpharm to Chinese Pharmaceutical Giant, Valued at Nearly 9 Trillion VND
Imexpharm’s AGM: Aiming for Four Consecutive Years of Record Profits, SK Has Not Yet Divested
Livzon is a leading Chinese pharmaceutical conglomerate, established in 1985, with a current charter capital of over 935 million Chinese Yuan (CNY). The group specializes in researching, producing, and developing pharmaceuticals, modern medicines, traditional Chinese medicine, and raw materials, operating in more than 30 countries worldwide, including the U.S., EU, South Korea, Japan, and Southeast Asia.
– 15:22 15/01/2026
IMEXPHARM Partners with VILA 2025 National Lung Science Conference
Accompanying the National Lung Science Conference VILA 2025 in Can Tho this November, where over 1,000 respiratory specialists will converge, Imexpharm reaffirms its unwavering commitment to advancing community respiratory health.
Missed the Vingroup Train? You’re Not Alone – Even Korean Chaebols Dumped VIC Before Its Surge
Many investors are left in awe, watching Vingroup’s high-speed train soar ahead, fully booked and sold out even before the VIC stock skyrockets.
South Korean Conglomerate Exits Masan, Vingroup as Ministry of Finance Releases Competency Assessment Results
Since establishing its presence in Vietnam, SK Group has invested over $3.5 billion, primarily through capital contributions and share acquisitions in major corporations such as Vingroup, Masan, Petrolimex, PV OIL, and Imexpharm. However, after years of strategic adjustments, the conglomerate has gradually divested, reducing its total investment value to approximately $650 million.
IMEXPHARM’s Gross Revenue Surges 21% to VND 2,118 Billion in First Nine Months of 2025
On October 20, 2025, Imexpharm announced its business results for the first nine months of 2025, reporting net revenue of VND 1,800 billion, a 16% increase compared to the same period last year, with EBITDA margin rising to 22.3%.
IMEXPHARM’s Net Revenue Surges 16% to VND 1.8 Trillion in First Nine Months of 2025
In September 2025, Imexpharm’s pre-tax profit surged by 101%, while EBITDA grew by 48%. For the first nine months of 2025, the company recorded gross revenue of VND 2,118 billion and net revenue of VND 1,800 billion, marking increases of 21% and 16%, respectively.
